XML 132 R29.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Segment Reporting [Abstract] |
Schedule of worldwide net revenues | The following table details AbbVie’s worldwide net revenues:
|  | Three months ended March 31, |  |  |  |  |  |
(in millions) |  | 2026 |  | 2025 |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |
Skyrizi | United States | $ | 3,775 |  |  | $ | 2,919 |  |  |  |  |  |  |
| International | 708 |  |  | 506 |  |  |  |  |  |  |
| Total | $ | 4,483 |  |  | $ | 3,425 |  |  |  |  |  |  |
Rinvoq | United States | $ | 1,405 |  |  | $ | 1,220 |  |  |  |  |  |  |
| International | 714 |  |  | 498 |  |  |  |  |  |  |
| Total | $ | 2,119 |  |  | $ | 1,718 |  |  |  |  |  |  |
Humira | United States | $ | 357 |  |  | $ | 744 |  |  |  |  |  |  |
| International | 331 |  |  | 377 |  |  |  |  |  |  |
| Total | $ | 688 |  |  | $ | 1,121 |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |
Vraylar | United States | $ | 902 |  |  | $ | 763 |  |  |  |  |  |  |
| International | 3 |  |  | 2 |  |  |  |  |  |  |
| Total | $ | 905 |  |  | $ | 765 |  |  |  |  |  |  |
Botox Therapeutic | United States | $ | 842 |  |  | $ | 723 |  |  |  |  |  |  |
| International | 167 |  |  | 143 |  |  |  |  |  |  |
| Total | $ | 1,009 |  |  | $ | 866 |  |  |  |  |  |  |
Ubrelvy | United States | $ | 330 |  |  | $ | 233 |  |  |  |  |  |  |
| International | 9 |  |  | 7 |  |  |  |  |  |  |
| Total | $ | 339 |  |  | $ | 240 |  |  |  |  |  |  |
Qulipta | United States | $ | 250 |  |  | $ | 172 |  |  |  |  |  |  |
| International | 46 |  |  | 21 |  |  |  |  |  |  |
| Total | $ | 296 |  |  | $ | 193 |  |  |  |  |  |  |
Vyalev | United States | $ | 89 |  |  | $ | 6 |  |  |  |  |  |  |
| International | 112 |  |  | 57 |  |  |  |  |  |  |
| Total | $ | 201 |  |  | $ | 63 |  |  |  |  |  |  |
Other Neuroscience | United States | $ | 46 |  |  | $ | 75 |  |  |  |  |  |  |
| International | 79 |  |  | 80 |  |  |  |  |  |  |
| Total | $ | 125 |  |  | $ | 155 |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |
Venclexta | United States | $ | 341 |  |  | $ | 312 |  |  |  |  |  |  |
| International | 429 |  |  | 353 |  |  |  |  |  |  |
| Total | $ | 770 |  |  | $ | 665 |  |  |  |  |  |  |
|  | Three months ended March 31, |  |  |  |  |  |
(in millions) |  | 2026 |  | 2025 |  |  |  |  |  |
Imbruvica | United States | $ | 332 |  |  | $ | 529 |  |  |  |  |  |  |
| Collaboration revenues | 224 |  |  | 209 |  |  |  |  |  |  |
| Total | $ | 556 |  |  | $ | 738 |  |  |  |  |  |  |
Elahere | United States | $ | 160 |  |  | $ | 165 |  |  |  |  |  |  |
| International | 38 |  |  | 14 |  |  |  |  |  |  |
| Total | $ | 198 |  |  | $ | 179 |  |  |  |  |  |  |
Epkinly | Collaboration revenues | $ | 51 |  |  | $ | 36 |  |  |  |  |  |  |
| International | 32 |  |  | 15 |  |  |  |  |  |  |
| Total | $ | 83 |  |  | $ | 51 |  |  |  |  |  |  |
Other Oncology | United States | $ | 24 |  |  | $ | — |  |  |  |  |  |  |
Aesthetics |  |  |  |  |  |  |  |  |
Botox Cosmetic | United States | $ | 371 |  |  | $ | 295 |  |  |  |  |  |  |
| International | 297 |  |  | 261 |  |  |  |  |  |  |
| Total | $ | 668 |  |  | $ | 556 |  |  |  |  |  |  |
Juvederm Collection | United States | $ | 85 |  |  | $ | 75 |  |  |  |  |  |  |
| International | 147 |  |  | 156 |  |  |  |  |  |  |
| Total | $ | 232 |  |  | $ | 231 |  |  |  |  |  |  |
Other Aesthetics | United States | $ | 248 |  |  | $ | 270 |  |  |  |  |  |  |
| International | 38 |  |  | 45 |  |  |  |  |  |  |
| Total | $ | 286 |  |  | $ | 315 |  |  |  |  |  |  |
Other Key Products |  |  |  |  |  |  |  |  |
Mavyret | United States | $ | 183 |  |  | $ | 142 |  |  |  |  |  |  |
| International | 168 |  |  | 164 |  |  |  |  |  |  |
| Total | $ | 351 |  |  | $ | 306 |  |  |  |  |  |  |
Creon | United States | $ | 361 |  |  | $ | 355 |  |  |  |  |  |  |
Linzess | United States | $ | 272 |  |  | $ | 139 |  |  |  |  |  |  |
| International | 11 |  |  | 9 |  |  |  |  |  |  |
| Total | $ | 283 |  |  | $ | 148 |  |  |  |  |  |  |
All other |  | $ | 1,025 |  |  | $ | 1,253 |  |  |  |  |  |  |
Total net revenues | $ | 15,002 |  |  | $ | 13,343 |  |  |  |  |  |  |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration